Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor–Positive Breast Cancer

Endocrine therapy with or without CDK4/6 inhibitors is the most commonly used frontline treatment option for metastatic hormone receptor–positive breast cancer. Approximately, 25% to 30% of women may have resistance to endocrine therapy, especially in the setting of certain genomic mutations in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarma, Maithreyi, Abdou, Yara, Dhakal, Ajay, Gandhi, Shipra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747096/
https://www.ncbi.nlm.nih.gov/pubmed/33402826
http://dx.doi.org/10.1177/1178223420976387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747096/
https://www.ncbi.nlm.nih.gov/pubmed/33402826
http://dx.doi.org/10.1177/1178223420976387

Ejemplares similares